Back to bill feed
S. 4355 (119th Congress)Committee
Sign in to get alertsDrug Deal Disclosure Act
Read the record. Not the rhetoric.
See how your representatives voted on this bill.
DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Alignment with your views
Sign in and take the values quiz to see how this bill lines up with what you've said.
Summary
AI-generated summary — verify against full text
The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release all documents, communications, and agreements relating to drug pricing deals between federal agencies and pharmaceutical manufacturers entered into since January 20, 2025. The bill mandates disclosure within 30 days of enactment and covers agreements involving most-favored-nation pricing, direct-to-consumer sales, import exemptions, investment commitments, demonstration project exemptions, Strategic National Stockpile contributions, and FDA priority review vouchers. The bill permits withholding only of proprietary pricing information and information legally protected from disclosure, while prohibiting withholding based on reputational or political sensitivity. The bill also requires congressional reports and a joint CBO-GAO analysis of the economic and budgetary effects of disclosed agreements.
Values analysis
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
How your representatives voted
Sign in to see how your representatives voted on this bill.